Foghorn Therapeutics Third Quarter 2024 Earnings Beats Expectations
| FHTX Stock | USD 4.80 0.21 4.58% |
Slightly above 54% of Foghorn Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Foghorn Therapeutics suggests that some traders are interested. Foghorn Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Foghorn Therapeutics' earnings reports, geopolitical events, and overall market trends.
Foghorn |
Foghorn Therapeutics Third Quarter 2024 Results Key Financial Results Revenue US7.81m down 55 percent from...
Read at simplywall.st
 |
Foghorn Therapeutics Fundamental Analysis
We analyze Foghorn Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Foghorn Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Foghorn Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Foghorn Therapeutics stock to make a market-neutral strategy. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics with similar companies.
Peers
Foghorn Therapeutics Related Equities
| CSBR | Champions Oncology | 18.78 | ||||
| PRLD | Prelude Therapeutics | 11.20 | ||||
| STTK | Shattuck Labs | 10.74 | ||||
| CCCC | C4 Therapeutics | 7.10 | ||||
| IPSC | Century Therapeutics | 6.73 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.43 | ||||
| MLYS | Mineralys Therapeutics, | 4.08 | ||||
| EWTX | Edgewise Therapeutics | 2.55 | ||||
| MOLN | Molecular Partners | 2.53 | ||||
| CGEM | Cullinan Oncology | 2.34 | ||||
| STOK | Stoke Therapeutics | 1.95 | ||||
| RZLT | Rezolute | 1.75 | ||||
| KYMR | Kymera Therapeutics | 1.71 | ||||
| MNOV | MediciNova | 1.43 | ||||
| PMVP | Pmv Pharmaceuticals | 1.31 | ||||
| NRIX | Nurix Therapeutics | 1.03 | ||||
| GLUE | Monte Rosa | 0.84 |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.